Segment-wise performance

Johnson & Johnson (JNJ) reported 8.4% growth in operating revenues and a 4.2% positive impact of foreign exchange to $20.0 billion in 1Q18 as compared to revenues of $17.8 billion during 1Q17. Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.

Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18

The above chart shows revenues for each of Johnson & Johnson’s business segments since 1Q17.

Segment-wise revenues

The Pharmaceuticals segment reported growth of 19.4% in revenues to $9.8 billion during 1Q18 as compared to $8.2 billion during 1Q17. The revenues increased 15.1% at constant exchange rates, while foreign exchange had a 4.3% positive impact on revenues during 1Q18. The growth was driven by Stelara and Simponi/Simponi Aria from the immunology franchise, Edurant and Prezista/Prezcobix/Rezolsta/Symtuza from the infectious diseases franchise, Invega Sustenna/Xeplion/Trinza/Trevicta from the neuroscience franchise, Darzalex, Imbruvica, Velcade, and Zytiga from the oncology franchise, Xarelto and Procrit/Eprex from the cardiovascular franchise, and pulmonary hypertension products.

The consumer segment reported growth of 5.3% in revenues to $3.4 billion during 1Q18 as compared to $3.2 billion during 1Q17. Revenues rose 1.3% at constant exchange rates, while foreign exchange had a 4.0% positive impact on the revenues for the consumer segment. The revenue growth was driven by the strong performance of baby care products, beauty products, oral care products, over-the-counter products, and women’s health products, partially offset by lower sales of wound care products during 1Q18.

The medical devices segment reported growth of 7.5% in revenues to $6.8 billion during 1Q18 as compared to $6.3 billion during 1Q17. The revenues rose 3.2% at constant exchange rates, while the foreign exchange had a 4.3% positive impact on revenues for the medical devices segment. The 1Q18 growth for the medical devices segment was driven by the strong performance of the following:

  • interventional solutions
  • hip and trauma products from the orthopedic products portfolio
  • surgery products
  • vision care products

After excluding the impact of acquisitions and divestitures, the pharmaceutical segment reported growth of 7.5% in worldwide sales, the consumer segment reported growth of 2.0% in worldwide sales, while the medical devices segment reported growth of 1.1% in worldwide sales.

The First Trust NASDAQ Pharmaceuticals ETF (FTXH) holds 7.9% of its total investments in Johnson & Johnson (JNJ), 8.1% in Pfizer (PFE), 6.3% in Bristol-Myers Squibb (BMY), and 4.1% in Eli Lilly (LLY).

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!

Latest articles

This year, Pfizer (PFE) stock has fallen 0.34% and Bristol-Myers Squibb (BMY) stock has fallen 6.48%. Both companies are focused on strengthening their position in the high-growth oncology and immunology markets. Let's take a closer look at each.

Walt Disney’s (DIS) latest movie, Toy Story 4, has reportedly broken records in the opening weekend with $118 million in sales. However, the opening weekend collection was behind analysts’ expectations of at least $150 million in the first weekend.

24 Jun

Will Home Depot’s Upward Momentum to Continue?

WRITTEN BY Rajiv Nanjapla

As of June 21, Home Depot (HD) was trading at $209.39, which implies a rise of 9.7% since the announcement of its first-quarter earnings on May 21. Also, the company was trading at a premium of 32.4% from its 52-week low of $158.09 and a discount of 2.8% from its 52-week high of $215.43.

On June 21, Aurora Cannabis (ACB) made an announcement that indicated that it will move towards higher margin vape products. In addition, the company also believes concentrates and edibles will command higher margins. In anticipation of this development, the company announced the expansion of its facility to capitalize on growth related to these segments.

Shares of Mondelēz International (MDLZ) are scaling new heights thanks to its stellar gains so far this year. Mondelēz stock is up 38.0% on a YTD (year-to-date) basis, and it closed at $55.25—just a shade lower than its 52-week high of $55.71—on June 21.

24 Jun

How Long Will Facebook's Libra Fuel Bitcoin Rally?

WRITTEN BY Mayur Sontakke, CFA, FRM

Ever since the news about Facebook’s (FB) cryptocurrency project broke, Bitcoin has rallied on the hope that Facebook’s entry in the space will help make cryptocurrencies mainstream. Facebook’s cryptocurrency will be called Libra and will be governed by an association with 28 founding members across industries.

172.31.38.64